Concord Biotech’s shares rose as much as 5.2 % to an intraday high of ₹1,572.30 per unit on the National Stock Exchange on Monday, September 21, up from Friday’s close of ₹1,494.40. The rally followed the company’s announcement that its board will convene on September 23 to consider a proposal for a bonus issue of equity shares to existing shareholders. At 11:19 AM the stock traded 4.31 % higher at ₹1,558.80. Over the week the scrip has advanced 4 % and 17 % year‑to‑date.

Concord Biotech’s 52‑week high reached ₹1,704 per unit on September 19, 2025, while the shares touched a year‑low of ₹987 on April 2, 2026. The company’s market capitalisation stood at ₹16,333.73 crore as of September 21, 2026, according to NSE data. The board’s upcoming meeting on September 23, 2026 will also consider the declaration of bonus equity shares, subject to shareholder approval, as stated in a regulatory filing dated September 19. Additionally, the company reported that the US FDA inspected its formulation facility in Ahmedabad on September 18, 2026, issuing one minor procedural observation unrelated to GMP, which Concord Biotech said would not materially affect operations.

The FDA’s inspection concluded on September 18, 2026, with a single procedural observation that was not related to Good Manufacturing Practices. Concord Biotech stated it would submit a comprehensive response within the stipulated timeline and does not expect the observation to have any material impact on current business operations or existing supplies from the facility. Earlier, the firm reported a 32.8 % year‑on‑year increase in net profit to ₹58.5 crore for the April‑June quarter of FY27, up from ₹44.05 crore in the same period last year, and revenue rose 26.2 % YoY to ₹257.4 crore.

Concord Biotech’s Q1 FY27 results showed a net profit of ₹58.5 crore, a 32.8 % YoY jump from ₹44.05 crore in Q1 FY26. Operating revenue reached ₹257.4 crore, up 26.2 % YoY from ₹204 crore in the preceding quarter. The company’s earnings growth reflects increased sales and operational efficiencies, according to the financial statements released on September 21, 2026. The market capitalisation was ₹16,333.73 crore as of September 21, 2026, and the shares had risen 4 % over the week and 17 % year‑to‑date.

The board’s meeting on September 23, 2026 will consider a proposal to declare bonus equity shares to existing shareholders, subject to shareholder approval, as per a regulatory filing dated September 19. The announcement has already spurred a 5 % intraday rally, with the scrip hitting a 52‑week high of ₹1,704 on September 19, 2025, and a year‑low of ₹987 on April 2, 2026. Investors are monitoring the outcome closely as the company’s performance continues to improve. Further details will be disclosed after the board’s decision, and shareholders will be notified of any changes to the bonus scheme.